1 Ichihara K, Ozarda Y, Barth JH, Klee G, Qiu L, Erasmus R, et al. on behalf of the Committee on Reference Intervals and Decision Limits, International Federation of Clinical Chemistry and Laboratory Medicine. A global multicenter study on reference values: 1. Assessment of methods for derivation and comparison of reference intervals. Clin Chim Acta. 2017;467:70–82.
2 Katayev A, Balciza C, Seccombe DW. Establishing Reference Intervals for Clinical La-boratory Test Results. Is There a Better Way? Am J Clin Pathol. 2010;133:180–6.
3 Sibille M, Deigat N, Durieu I, Guillaumont M, Morel D, Bienvenu J, Massignon D, et al. Laboratory data in healthy volunteers: reference values, reference changes, screening and laboratory adverse event limits in Phase I clinical trials. Eur J Clin Pharmacol. 1999;55:13–9.
4 Favrat B; Guessous I; Gonthier A; Cornuz J. Prolonged or chronic fatigue of unknown origin. Fatigue prolongée ou chronique d’origine indéterminée. Rev Med Suisse. 2015;11(471):931–5.
5 Bove-Fenderson E, Mannstadt M. Hypocalcemic disorders. Best Pract Res Clin Endocrinol Metab. 2018;32(5):639–56.
6 Cusano NE, Maalouf NM, Wang PY, Zhang C, Cremers SC, Haney EM, Bauer DC et al. Normocalcemic Hyperparathyroidism and Hypoparathyroidism in Two Community-Based Nonreferral Populations. J Clin Endocrinol Metab. 2013;98:2734–41.
7 Kaufmann-Didisheim N. Définition de l’intervalle de référence de la calcémie dans une population hospitalière. Thèse Faculté de Médecine, Université de Lausanne, 1989.
8 Fong J, Khan A. Hypocalcemia Updates in diagnosis and management for primary care. Can Fam Physician. 2012;58:158–62.
9 Glück M, Locher R, Fehr Th. Hypokalzämie. Praxis. 2018;107(7):353–9.
10 Jain N; Reilly RF. Hungry bone syndrome. Current Opinion in Nephrology & Hypertension. 2017;26(4):250–5.
11 Reinwald S, Weaver CM, Kester JJ. The health benefits of calcium citrate malate: a review of the supporting science. Adv Food Nutr Res. 2008;54:219–346.
12 Ahmed F, Mohamed A. Magnesium: The Forgotten Electrolyte—A Review on Hypomagnesemia. Med Sci (Basel). 2019;7(4):56–69.
13 Schimatschek HF, Rempis R. Prevalence of hypomagnesemia in an unselected German population of 16,000 individuals. Magnesium Research. 2001;14:283–290.
14 Manuel y Keenoy B, Moorkens G, Vertommen J, Noe M, Nève J, De Leeuw I. Magnesium Status and Parameters of the Oxidant-Antioxidant Balance in Patients with Chronic Fatigue: Effects of Supplementation with Magnesium. Journal of the American College of Nutrition. 2000;19(3):374–82.
15 Gröber U. Magnesium and Drugs. Int J Mol Sci. 2019;20:2094–108.
16 Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, Srivali N, Edmonds PJ, Ungprasert P, O’Corragain OA, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Renal Failure. 2015;37(7):1237–41.
17 Janett S, Camozzi P, Peeters GG, Lava SA, Goeggel Simonetti GD, Simonetti GB, Bianchetti MG, Milani GP. Hypomagnesemia Induced by Long-Term Treatment with Proton-Pump Inhibitors. Gastroenterology research & practice. 2015;951768.
18 Nechifor M. Magnesium in addiction – a general view. Magnesium Research. 2018; 31(3):90–8.
19 Gaasbeek A, Meinders AE. Hypophosphatemia: An update on its etiology and treatment. The American Journal of Medicine. 2005;118:1094–101.
20 Camp MA, Allon M. Severe hypophosphatemia in hospitalized patients. Miner. Electrolyte Metab. 1990;16:365–8.
21 Subramanian R, Khardori R. Severe hypophosphatemia. Pathophysiologic implications, clinical presentations, and treatment. Medicine. 2000;79(1):1–8.
22 Anastasilakis DA, Makras P, Polyzos SA, Anastasilakis AD and Part of the COMBO ENDO TEAM 2017. Asymptomatic and normocalcemic hyperparathyroidism, the silent attack: a combo-endocrinology overview. Hormones. 2019;18:65–70.
23 Friedli N, Stanga Z, Sobotka L, Culkin A, Kondrup J, Laviano A, et al. Revisiting the refeeding syndrome: Results of a systematic review. Nutrition. 2017;35:151–60.
24 De Lorenzo F, Hargreaves J, Kakkar VV. Phosphate diabetes in patients with chronic fatigue syndrome. Postgraduate Medical Journal. 1998;74(870):229–32.
25 Krapf R, Vetsch R, Vetsch W, Hulter HN. Chronic metabolic acidosis increases the serum concentration of 1,25-dihydroxyvitamin D in humans by stimulating its production rate. Critical role of acidosis-induced renal hypophosphatemia. Journal Clinical Investigation. 1992;90:2456–246.
26 Juppner H, Wolf M, Salusky IB. FGF-23: more than a regulator of renal phosphate handling?. J Bone Miner Res. 2010;25:2091–7.
27 Dadoniene J, Miglinas M, Miltiniene D, Vajauskas D, Seinin D, Butenas P, Kacergius T. Tumour-induced osteomalacia: a literature review and a case report. World Journal of Surgical Oncology. 2016;14(1):4.
28 Goldsweig BK, Carpenter TO. Hypophosphatemic rickets: lessons from disrupted FGF control of phosphorus homeostasis. Current Osteoporosis Reports. 2015;13(2):88–97.
29 Drivakos N, Hüsler C, Binet I. Hypophosphatämie – was der Hausarzt wissen muss. Hypophosphatemia – Diagnostics and Treatment. Praxis. 2017;106(8):399–403.
30 Zoller H, Schaefer B, Glodny B. Iron-induced hypophosphatemia: an emerging complication. Curr Opin Nephrol Hypertens. 2017;26:266–75.
31 Schaefer B, Würtinger P, Finkenstedt A, et al. Choice of high-dose intravenous iron preparation determines hypophosphatemia risk. PLoS ONE. 2016;11:e0167146.
32 Wolf M, Chertow GM, Macdougall IC, Kaper R, Krop J, Strauss W. Randomized trial of intravenous iron-induced hypophosphatemia JCI Insight. 2018;3(23):e124486.
33 Detlie TE, Lindstrøm JC, Jahnsen ME, Finnes E, Zoller H, Moum B, Jahnsen J. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside. Aliment Pharmacol Ther. 2019;50(4):397–406.
34 Zoller HS, de Muckadell P, Wolf M. Pooled analysis of the PHOSPHARE-IDA 04/05 studies: findings relevant to respiratory muscle function. Poster 51, 20th Annual NATA Symposium, Berlin, 4–5 April 2019.
35 Wirth R, Diekmann R, Janssen G, Fleiter O, Fricke L, Kreilkamp A, et al. Arbeitsgruppe Ernährung und Stoffwechsel der Deutschen Ges. für Geriatrie (DGG). Refeeding-Syndrom. Pathophysiologie, Risikofaktoren, Prophylaxe und Therapie. Internist. 2018;59:326–33.
36 Rio A, Whelan K, Goff L, Reidlinger DP, Smeeton N. Occurrence of refeeding syndrome in adults started on artificial nutrition support: prospective cohort study. BMJ Open. 2013;3:e002173.
37 Marik PE, Bedigian MK. Refeeding Hypophosphatemia in Critically Ill patients in an Intensive Care Unit. Arch Surg. 1996; 131:1043–7.
38 Felsenfeld AJ, Levine BS. Approach to treatment of hypophosphatemia. American Journal of Kidney Diseases. 2012;60(4):655–61.
39 Haglin L .Using phosphate supplementation to reverse hypophosphatemia and phos-phate depletion in neurological disease and disturbance. Nutr Neurosci. 2016;19(5):213–23